WO2000037487A8 - INHIBITOREN DES INTEGRINS αvβ¿6? - Google Patents

INHIBITOREN DES INTEGRINS αvβ¿6?

Info

Publication number
WO2000037487A8
WO2000037487A8 PCT/EP1999/009842 EP9909842W WO0037487A8 WO 2000037487 A8 WO2000037487 A8 WO 2000037487A8 EP 9909842 W EP9909842 W EP 9909842W WO 0037487 A8 WO0037487 A8 WO 0037487A8
Authority
WO
WIPO (PCT)
Prior art keywords
xaa
αvβ6 integrin
peptides
leu
integrin inhibitors
Prior art date
Application number
PCT/EP1999/009842
Other languages
English (en)
French (fr)
Other versions
WO2000037487A1 (de
Inventor
Beate Diefenbach
Alfred Jonczyk
Sabine Kraft
Ray Mehta
Original Assignee
Merck Patent Gmbh
Beate Diefenbach
Alfred Jonczyk
Sabine Kraft
Ray Mehta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SK805-2001A priority Critical patent/SK8052001A3/sk
Priority to AU19777/00A priority patent/AU770295B2/en
Priority to HU0104071A priority patent/HUP0104071A2/hu
Priority to BR9916323-3A priority patent/BR9916323A/pt
Priority to CA002355874A priority patent/CA2355874A1/en
Priority to KR1020017007309A priority patent/KR20010101178A/ko
Application filed by Merck Patent Gmbh, Beate Diefenbach, Alfred Jonczyk, Sabine Kraft, Ray Mehta filed Critical Merck Patent Gmbh
Priority to PL99348058A priority patent/PL348058A1/xx
Priority to JP2000589556A priority patent/JP2002533064A/ja
Priority to EP99963507A priority patent/EP1140989A1/de
Publication of WO2000037487A1 publication Critical patent/WO2000037487A1/de
Publication of WO2000037487A8 publication Critical patent/WO2000037487A8/de
Priority to NO20013013A priority patent/NO20013013D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung beschreibt neuartige Peptide, welche als Liganden des Integrins αvβ6 biologisch wirksam sind. Diese Peptide weisen alle ein gemeinsames Strukturmotiv, nämlich - Asp Leu Xaa Leu -, bzw. in einer bevorzugten Form - Arg Xaa Asp Leu Xaa Xaa Leu Arg - auf, wobei Xaa für einen beliebigen Aminosäurerest steht. Die erfindungsgemäßen Peptide können als wirksame Inhibitoren des αvβ6-Integrin-Rezeptors und somit zur Behandlung verschiedener Krankheiten und pathologischer Befunde eingesetzt werden.
PCT/EP1999/009842 1998-12-19 1999-12-11 INHIBITOREN DES INTEGRINS αvβ¿6? WO2000037487A1 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU19777/00A AU770295B2 (en) 1998-12-19 1999-12-11 AlphaVbetaB integrin inhibitors
HU0104071A HUP0104071A2 (hu) 1998-12-19 1999-12-11 Az alfavbéta6-integrint gátló vegyületek
BR9916323-3A BR9916323A (pt) 1998-12-19 1999-12-11 Inibidores da integrina alfavbeta6
CA002355874A CA2355874A1 (en) 1998-12-19 1999-12-11 .alpha.v.beta.6 integrin inhibitors
KR1020017007309A KR20010101178A (ko) 1998-12-19 1999-12-11 αｖβ６ 인테그린 저해제
SK805-2001A SK8052001A3 (en) 1998-12-19 1999-12-11 Peptide compound, the use thereof and pharmaceutical composition comprising the same
PL99348058A PL348058A1 (en) 1998-12-19 1999-12-11 Αv
JP2000589556A JP2002533064A (ja) 1998-12-19 1999-12-11 インテグリンαｖβ６阻害剤
EP99963507A EP1140989A1 (de) 1998-12-19 1999-12-11 Inhibitoren des integrins alpha(v) beta(6)
NO20013013A NO20013013D0 (no) 1998-12-19 2001-06-18 <alfa>v<beta>6-integrininhibitorer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19858857.7 1998-12-19
DE19858857 1998-12-19

Publications (2)

Publication Number Publication Date
WO2000037487A1 WO2000037487A1 (de) 2000-06-29
WO2000037487A8 true WO2000037487A8 (de) 2001-03-29

Family

ID=7891834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/009842 WO2000037487A1 (de) 1998-12-19 1999-12-11 INHIBITOREN DES INTEGRINS αvβ¿6?

Country Status (10)

Country Link
EP (1) EP1140989A1 (de)
JP (1) JP2002533064A (de)
CN (1) CN1335853A (de)
AR (1) AR022395A1 (de)
BR (1) BR9916323A (de)
CA (1) CA2355874A1 (de)
CZ (1) CZ20012212A3 (de)
NO (1) NO20013013D0 (de)
WO (1) WO2000037487A1 (de)
ZA (1) ZA200105929B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
DE19933173A1 (de) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
BRPI0308585B8 (pt) 2002-03-13 2021-05-25 Biogen Idec Inc anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
CN1747966A (zh) * 2003-02-06 2006-03-15 默克专利有限公司 肽磺酰胺
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
KR20090027241A (ko) 2006-07-10 2009-03-16 바이오겐 아이덱 엠에이 인코포레이티드 Ｓｍａｄ４-결핍 암의 성장을 억제하기 위한 조성물 및 방법
CA2658612C (en) 2006-08-03 2015-11-17 Astrazeneca Ab Antibodies directed to .alpha.v.beta.6 and uses thereof
AU2007354317A1 (en) * 2006-10-19 2008-12-04 Biogen Idec Ma Inc. Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6
WO2009093251A2 (en) * 2008-01-24 2009-07-30 Gavish-Galilee Bio Applications Ltd Reovirus vaccine based on sigma c protein sequence
WO2014007547A1 (en) * 2012-07-03 2014-01-09 Il Yang Pharm. Co.,Ltd. Novel peptides and use thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
EP3760202A1 (de) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitoren von (alpha-v)(beta-6)-integrin
RU2769702C2 (ru) 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Ингибиторы интегрина avb6
EP4086254A1 (de) 2018-08-29 2022-11-09 Morphic Therapeutic, Inc. Integrininhibitoren

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219515A (en) * 1987-02-10 1989-09-27 Wellcome Found Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope

Also Published As

Publication number Publication date
WO2000037487A1 (de) 2000-06-29
NO20013013L (no) 2001-06-18
AR022395A1 (es) 2002-09-04
ZA200105929B (en) 2003-03-18
EP1140989A1 (de) 2001-10-10
CN1335853A (zh) 2002-02-13
CZ20012212A3 (cs) 2001-09-12
BR9916323A (pt) 2001-10-30
NO20013013D0 (no) 2001-06-18
JP2002533064A (ja) 2002-10-08
CA2355874A1 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
WO2000037487A8 (de) INHIBITOREN DES INTEGRINS αvβ¿6?
GB9720054D0 (en) Biological products
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
IL142905A0 (en) Functional antagonists of hedgehog activity
WO2000016733A3 (en) Personal care compositions containing active proteins tethered to a water insoluble substrate
WO2003048205A3 (fr) Proteines a activite inhibitrice de l&#39;il-6
MXPA02000465A (es) Derivados ciclopeptidicos como inhibidores de la integrina alfav beta6.
MY104909A (en) Peptide compounds.
GB0020331D0 (en) Enzyme
WO2002092758A3 (en) Gastrokines and derived peptides including inhibitors
WO2000063415A8 (en) Dna encoding the human vanilloid receptor vr1
NZ591825A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating fatigue
WO2001045738A3 (en) Use of heat shock proteins to enhance production of chemokines by a cell
CA2340934A1 (en) Novel collectin
AU2957099A (en) Novel physiologically active peptides and utilization thereof
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
CA2406884A1 (en) Novel collectins
WO2001042287A3 (en) Putative human g-protein coupled receptors
EP1272514A4 (de) Für den menschlichen vanilloid-rezeptor vr3 kodierende dns
WO2002000686A3 (en) Bioelastomer nanomachines and biosensors
SE9401380D0 (sv) Ny celltillväxt-relaterad peptid och användning därav
EP0837074A3 (de) Biologisch aktives Fibronektin-Fragment als Krebsmetastasehemmstoff
EP1381388A4 (de) Herstellung von peptiden in pflanzen als n-terminale proteinfusionen mit virusmantel
CA2409546A1 (en) Peptides and derivatives thereof showing cell attachment, spreading and detachment activity
WO2002050100A3 (en) Diaminodicarboxylic acid: peptide-based gemini surfactant compounds used for drug delivery

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99814760.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 26/2000 UNDER (30) REPLACE "19858587.7" BY "19858857.7"

WWE Wipo information: entry into national phase

Ref document number: 1999963507

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 8052001

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1020017007309

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09868098

Country of ref document: US

ENP Entry into the national phase in:

Ref document number: 2355874

Country of ref document: CA

Ref document number: 2355874

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/006229

Country of ref document: MX

Ref document number: PV2001-2212

Country of ref document: CZ

ENP Entry into the national phase in:

Ref document number: 2000 589556

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/05929

Country of ref document: ZA

Ref document number: 19777/00

Country of ref document: AU

Ref document number: 200105929

Country of ref document: ZA

Ref document number: 1200100679

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: PV2001-2212

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1999963507

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017007309

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 19777/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020017007309

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999963507

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-2212

Country of ref document: CZ